Table 2.

Multivariate Regression Models of Predictors of Taking HAART 6 Months Later Among HIV-Seropositive Injection Drug Users (Logistic general Estimating Equations; INSPIRE Study, 2001–2005)

	Full sample (n = 1,225)		Participants in HIV primary care# (n = 1,040)
Characteristics	Adjusted OR	95% CI	Adjusted OR	95% CI
Individual-level factors
Education: ≤8th grade	0.55**	0.36, 0.83	0.54**	0.35, 0.85
Age, baseline	1.02*	1.00, 1.05	1.03*	1.00, 1.05
Drug use, current	0.65**	0.50, 0.86	0.67**	0.50, 0.90
CD4 count: <350	1.70***	1.28, 2.50	1.65**	1.23, 2.22
Positive attitude: health benefits of HAART even if using drugs: strongly agreeb	1.45*	1.07, 1.98	1.48*	1.06, 2.06
Structural factors
Health care coverage, any	2.29***	1.57, 3.34	2.13***	1.40, 3.25
Stable housing	1.90*	1.15, 3.15	2.05*	1.11, 3.77
HIV primary care visits:  >4 in past 6 months	1.77***	1.35, 2.32	1.44*	1.09, 1.91
Interpersonal factor
Patient-provider engagement: perfect	—	—	1.45*	1.09, 1.93

^#At least one visit in the prior 2 years.

⁺p < 0.10, *p < 0.05, **p < 0.01, by the Wald statistic.

^aOdds of taking HAART for each additional increase in 1 unit on scale.

^bVersus strongly disagree, disagree, or agree.